IL-12-and IL-23 in health and disease |
| |
| Affiliation: | 1. National Institute for Health Research (NIHR) Birmingham Biomedical Research Centre, Birmingham, UK;2. Institute of Immunology and Immunotherapy, University of Birmingham, Birmingham, UK;3. Weiss School of Natural Sciences, Rice University, Houston, TX, USA;4. Academic Department of Medical Genetics, University of Cambridge, Cambridge, UK;5. Institute of Cellular Medicine, Newcastle University, Newcastle-upon-Tyne, UK;6. NIHR Newcastle Biomedical Research Centre, Newcastle University, Newcastle-upon-Tyne, UK;7. Institute of Inflammation and Ageing and NIHR Birmingham Biomedical Research Centre, University of Birmingham, Birmingham, UK;8. University Hospitals Birmingham, Birmingham, UK;9. Toronto Centre for Liver Disease, University Health Network, University of Toronto, Toronto, Canada;1. Immunology in Cancer and Infection Laboratory, Queensland Institute of Medical Research, Herston, 4006, Queensland, Australia;2. Cancer Immunoregulation and Immunotherapy Laboratory, Queensland Institute of Medical Research, Herston, 4006, Queensland, Australia;3. School of Medicine, University of Queensland, Herston, 4006, Queensland, Australia |
| |
| Abstract: | Interleukin (IL)-12 and IL-23 play important roles in the development of experimental autoimmune disease models and numerous afflictions affecting humans. Preclinical data over the last 20 years combined with successful clinical trials has identified a clear relationship between IL-12, IL-23 and the generation of pathogenic T helper cells capable of orchestrating tissue inflammation. Observations made in the clinic have shown that IL-12p40, a common subunit shared by IL-12 and IL-23, is critical to pathologies associated with psoriasis, inflammatory bowel disease (IBD) and tumor growth. These advancements have set in motion the development of a number of potential therapeutics aimed at manipulating IL-12/23 signaling pathways in both mice and humans. This review will discuss a brief history of the understanding and expansion of the IL-12 cytokine family, some difficulties associated with preclinical data interpretation and finally the medicinal interventions that have been developed to combat IL-12/23-driven autoimmune disorders. |
| |
| Keywords: | Cytokines Inflammation Treatment IL-12 family Autoimmunity |
| 本文献已被 ScienceDirect 等数据库收录！ |
|
